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RESEARCH LETTER
Infliximab With Low-Dose Methotrexate
for Prevention of Postsurgical Recurrence
of Ileocolonic Crohn Disease
P ostsurgical recurrence of Crohn disease is a veryfrequent event, and none of the drugs used forthe purpose has really shown a clear-cut effi-
cacy.1 Infliximab, amonoclonal antibody anti–tumor ne-
crosis factor (anti–TNF-), is very effective in the treat-
ment of active Crohn disease, but its benefit in preventing
postoperative recurrence is still unknown. Yet, its im-
pact, both medical and economic, could be major.2 Lo-
cal injection of infliximab for early mucosal postopera-
tive recurrence of Crohn disease seems feasible and safe;
however, preliminary results have been disappointing.3
By contrast, a patient treated with intravenous inflixi-
mab immediately after surgery to prevent the recur-
rence of colonic Crohn disease has been disease free for
48 months after surgery.4
Methods. In the present prospective pilot study, inflix-
imab was administered 2 weeks after surgery, along with
low-dose methotrexate, whereas controls were treated
with mesalamine alone. There is no evidence for a role
of methotrexate in preventing recurrence5; however, we
elected to use this drug because it is known to reduce
long-term immunogenicity of infliximab.6 This is not a
randomized study: the decision to include a patient in
one group or the other, given the experimental nature
of the infliximab-based preventive strategy, was solely
based on the full understanding and approval (with writ-
ten informed consent) of each patient. Before surgery,
patients to be treated with infliximabwere screened (pu-
rified protein derivative skin test, chest radiography, and
careful history taking) and were found negative for la-
tent tuberculosis. They were also evaluated (and found
negative) for past and present cardiac, neurologic, lym-
phoproliferative, and other neoplastic diseases. After sur-
gery, patients were subjected to endoscopy at 12 and 24
months; small-bowel enteroclysis or magnetic reso-
nance imaging at 12 and 24 months; and physical ex-
aminationwith interviews, togetherwith an extensive bat-
tery of blood tests (complete blood cell count; erythrocyte
sedimentation rate; C-reactive protein, albumin, electro-
lyte, autoantibody, and thyroid hormone levels; and liver
and renal function tests) every 3months. Infliximab was
given as a slow intravenous infusion at the dosage of 5
mg/1 kg of bodyweight, with an intravenous 100-mg bo-
lus hydrocortisone starting from 2 weeks after surgery,
followed by standard maintenance treatment (2, 6, and
then every 8 weeks) and therapy with low-dose metho-
trexate (10 mg/wk by mouth).
Patients in the control group were also subjected to
endoscopy and small-bowel enteroclysis ormagnetic reso-
nance imaging once a year andphysical examinationswith
interviews and blood tests every 3months. Controls were
given mesalamine-coated tablets, 800 mg 3 times daily,
starting from 2 weeks after surgery.
In both groups, the use of all medications was discon-
tinued at least a month before surgery. No other medica-
tions were allowed except for occasional tablets of
paracetamol or nonsteroidal anti-inflammatory drugs. Re-
currence was defined as any evidence of disease at 2 years
according to simplified endoscopic or clinical criteria. In
particular, clinical relapse was defined as a score of 2 or
greater on the clinical recurrence grading scale (where 1
indicates absent; 2,mild; 3,moderate; and 4, severe symp-
toms) recently proposed by Hanauer et al,7 while endo-
scopic relapse was defined as a score of 2 or greater on the
scale of Rutgeerts et al.8 The study protocol was ap-
proved by the institution ethics committee.
The Table illustrates the patients included in the study
and their clinical features. Sevenpatients in total (3women
and 4 men) were treated postoperatively with inflixi-
mab and low-dose methotrexate. Ages ranged from 23
to 64 years (median, 36 years). Of these patients, 4 had
an ileocecal resection, 1 a segmental ileal resection (he
had been previously subjected to ileocecal resection), and
2 a segmental sigmoid resection (1 of these patients pre-
viously underwent ileocecal resection). Indications for
resection included disease activity (2 patients) and stric-
ture (5 patients). The disease had been present for amini-
mum of 3 to a maximum of 14 years (median, 7 years).
Two patients currently smoke, while 1 is taking oral
contraceptives.
The clinical features of the control group are also il-
lustrated in the Table. Sixteen patients (5 women and
11 men) in total were operated on and treated postop-
eratively with mesalamine. Ages ranged from 23 to 70
years (median, 40.5 years). Nine patients underwent il-
eocecal resection (1 of whom had previously undergone
segmental sigmoid resection); 1, proctocolectomy; 2, right
hemicolectomy plus ileal resection; 1, left hemicolec-
tomy; 1, cecal resection; 1, ileal resection; and 1, seg-
mental sigmoid resection. The reason for surgery was a
stricture in 8 patients, disease activity in 7, and com-
bined stricture and disease activity in 1. The disease
had been present for a minimum of 1 to a maximum of
23 years (median, 5.5 years). Four patients currently
smoke, while none was taking oral contraceptives.
In all cases, surgery was considered radical (ie, it com-
pletely removed the involved intestine). Preoperatory as-
sessment (endoscopy and radiology) had excluded dis-
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ease outside the operated location. Of the 23 patients,
none had operative or postoperative complications and
none was lost to follow-up.
Results.The results, summarized in the last columnof the
Table, show that in the group treated postoperativelywith
infliximab and low-dose methotrexate, none has had, af-
ter 2 years, endoscopic or clinical recurrence as defined in
the “Methods” section. No abnormalities were detected in
blood test results during the study period and at the 2-year
follow-up examination. We did not record any potential
adverse effect that could be attributed to these medica-
Table. Clinical Features of Patients With Crohn Disease and Treatment Results
Patient No./
Sex/Age, y
Disease
Duration,
y
Involved
Intestine
Type of
Surgery
Reason
for
Surgery
Previous
Surgery
Current
Smoking
Status
Oral
Contraceptives
After Surgery
Medication
Before
Surgerya
Recurrence After
Surgery at 2 y
(Type of Recurrence)
Infliximab
methotrexate
groupb
1/M/64 7 Ileocecal Ileocecal resection Stricture No No NA Mesalamine,
prednisone cycles
No
2/M/36 3 Ileocecal Ileocecal resection Stricture No No NA Mesalamine,
prednisone cycles
No
3/F/24 3 Sigmoid
colon
Segmental sigmoid
resection
Disease
activity
No No Never Mesalamine,
prednisone cycles
No
4/F/23 9 Sigmoid
colon
Segmental sigmoid
resection
Disease
activity
Yes Yes, 5-6/d No (only in
the past)
Mesalamine,
prednisone
cycles,
azathioprine
No
5/M/61 8 Ileum Ileal resection Stricture Yes Yes, 20/d NA Mesalamine No
6/F/40 14 Ileocecal Ileocecal resection Stricture No No Yes Mesalamine
prednisone cycles
No
7/M/32 4 Ileocecal Ileocecal resection Stricture No No NA Mesalamine No
Mesalamine
groupc
1/M/47 2 Ileocecal Ileocecal resection Stricture No No NA Mesalamine,
prednisone cycles
Yes (endoscopic and
clinical)
2/F/29 1 Ileocecal Ileocecal resection Disease
activity
No No No (only in
the past)
Mesalamine,
prednisone cycles
Yes (endoscopic)
3/F/42 19 Pancolitis Proctocolectomy Disease
activity
No In the
past
No (only in
the past)
Mesalamine,
prednisone
cycles, tacrolimus
Yes (endoscopic plus
fistula)
4/M/49 23 Ileocecal Ileocecal resection Stricture Yes No NA Mesalamine,
prednisone cycles
Yes (endoscopic)
5/M/41 6 Ileocecal Ileocecal resection Stricture No No NA Mesalamine,
prednisone
cycles,
cyclosporin IV
Yes (endoscopic)
6/F/23 8 Ileocecal Ileocecal resection Stricture No Yes, 5-6/d No (only in
the past)
Mesalamine,
prednisone cycles
Yes (endoscopic)
7/F/42 5 Ileum and
right
colon
Right
hemicolectomy
and ileal
resection
Disease
activity
No Yes, 20/d No (only in
the past)
Mesalamine,
prednisone cycles
Yes (endoscopic and
clinical)
8/M/47 3 Cecum Cecal resection Stricture No No NA Mesalamine,
prednisone cycles
No
9/M/34 1 Ileum Ileal resection Disease
activity
No No NA Mesalamine,
prednisone cycles
No
10/F/38 7 Left colon Left hemicolectomy Disease
activity
No In the
past
No (only in
the past)
Mesalamine No
11/M/40 1 Ileocecal Ileocecal resection Disease
activity
No In the
past
NA No medication No
12/M/39 10 Ileocecal Ileocecal resection Stricture No No NA Mesalamine,
prednisone cycles
Yes (endoscopic)
13/M/61 15 Ileocecal Ileocecal resection Stricture No Yes, 20/d NA Mesalamine Yes (endoscopic)
14/M/33 1 Ileocecal Ileocecal resection Stricture No In the
past
NA Mesalamine Yes (endoscopic)
15/M/70 6 Sigmoid
colon
Segmental sigmoid
resection
Disease
activity
No Yes, 5-6/d NA Mesalamine,
prednisone cycles
Yes (endoscopic and
clinical)
16/M39 1 Ileum and
right
colon
Right
hemicolectomy
and ileal
resection
Disease
activity and
stricture
No No NA Mesalamine,
prednisone cycles
Yes (endoscopic and
clinical)
Abbreviation: NA, not applicable.
aThe use of every medication was stopped at least 4 weeks before surgery.
bInfliximab, 5 mg/1 kg of body weight, was given with methotrexate, 10 mg/wk by mouth.
cThe mesalamine dosage was 2.4 g/d.
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tions. However, 2 patients showed transient and border-
line positivity for lupus anticoagulant but none of the typi-
cal features of frank systemic lupus erythematosus, a very
rare complication of infliximab treatment.9 All the pa-
tients in this group reported an excellent quality of life and
still receive maintenance treatment.
The group treated withmesalamine also tolerated the
drug well, and no adverse effects were recorded during
the study period.However, in contrast to the group treated
with infliximab and low-dosemethotrexate, only 4 of the
16 patients (25%) were disease free 2 years after sur-
gery. In particular, of the 12 patients with recurrent dis-
ease, 7 had endoscopic relapse, while 5 fulfilled both the
endoscopic and the clinical criteria of recurrence. Of the
latter patients, 1 developed a perianal fistula. Of the 12
patients with endoscopic recurrence, 9 had a score of 3
or greater on the clinical recurrence grading scale. Of the
5 patients with a clinical (as well as endoscopic) recur-
rence, 4 had a score of 3 or greater. Most patients with
any type of recurrence had elevation of the inflamma-
tory indexes and/or amodest tomoderate decrease in he-
moglobin level. These data are consistent with well-
known recurrence rates recently published in the
literature7,10 and further indicate that mesalamine is not
an effective therapy to prevent recurrence.11
The Figure shows the endoscopic appearance of the
mucosal anastomosis in 2 patients 2 years after ileocecal
resection and maintenance treatment with intravenous
infliximab with low-dose methotrexate (A) or mesala-
mine (B).
Comment.Althoughwe are well aware of themany limi-
tations of our study (eg, lack of randomization, small
sample size, and single-center experience), in our series
of patients, infliximab with low-dose methotrexate was
extremely effective in preventing postsurgical recur-
rence of Crohn disease. Although we cannot exclude a
priori an effect of methotrexate in preventing recur-
rence, the lack of previous evidence5 and the very small
dose used in this study argue against it.
The results of this study reinforce the hypothesis that
infliximab may actually be capable, if given early, to
change the natural history of Crohn disease. We believe
that amulticenter, randomized, controlled study to firmly
establish the impact of this medication on the inevita-
bility of disease recurrence12 is warranted.
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Figure. Endoscopic appearance of the mucosal anastomosis of 2 patients with Crohn disease 2 years after ileocecal resection and maintenance treatment with
infliximab and low-dose methotrexate (A) or mesalamine (B). Note the complete absence of macroscopic signs of inflammation in the patient treated with
infliximab and methotrexate as opposed to the extensive and large ulcerations—in a clear setting of postsurgical recurrence of Crohn disease—in the
mesalamine-treated patient. The latter patient also had moderate clinical symptoms (score of 3 on the clinical recurrence grading scale [see the “Methods”
section]).
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COMMENTS AND OPINIONS
Chronic Venous Disease
and Injection Drug Use
W e commendArmstrong
1 for documenting the
increasing age of injection drug users and re-
lating this to the epidemiology of blood-
borne pathogens.Wewish to highlight other chronic com-
plications occurring in injection drug users that have been
infrequently reported. We have studied one of these con-
ditions, chronicvenousdisease (CVD), extensively.Chronic
venous disease causes lower extremity edema, aching dis-
comfort, skin changes, and refractory and recurrent leg ul-
cers, resulting in a lifelong, progressively debilitating con-
dition. The development of CVD is influenced by the
condition of the veins and/or valves, ankle range of mo-
tion as part of the calf muscle pump, and the microcircu-
lation.2 The damage to the veins from injection drug use
(IDU) continues to evolve even after IDU has stopped. In
our work on injection drug users receiving methadone
maintenance treatment, we found an 87% point preva-
lenceofCVD,with52%of affectedpersonshaving themost
advanced stages of disease.3 Most damage appears to oc-
cur in persons who have injected in the groin, legs, and
feet. In injection drug users, CVD occurs in middle-aged
persons comparably younger than in the general popula-
tion in which CVD occurs in the sixth or seventh decade.
In a study of human immunodeficiency virus–positive per-
sons,we found that injectiondrugusershad less ankleplan-
tar anddorsiflexion and inversion-eversion than thosewho
did not inject drugs.4 A causal model supported the hy-
pothesis of anklemobility as amediator of the effect of IDU
on CVD. Significant impairment of quality of life oc-
curred with leg pain causing increased functional impair-
mentwithworseningCVD; stair climbingandwalkingwere
also adversely affected.5 Leg pain reduced effectiveness of
the calf muscle pump function. Low income and educa-
tional levels were common in our samples and are associ-
ated with less access to care and issues of health literacy.
We currently have funding to test specific hypotheses link-
ing leg pain, pump function, and general mobility to CVD
progression in 600 persons with a history of drug abuse.
We encourage researchers and clinicians to consider the
plethora of complications of drug use in addition to blood-
borne pathogens as persons who injected drugs continue
to age because these complications have an important im-
pact on quality of life and are an economic burden.
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Prisoners (Should) Count
I t is difficult to understand a survey of injection drugusers1 that ignores “institutionalized persons,” in-cluding, specifically, prisoners. The comment of the
author that the excluded individuals “represent less than
2% of the US population”1(p166) gives scant comfort. The
incarcerated population in the United States numbers
more than 2.3 million persons,2 and a significant pro-
portion of the inmates are injection drug users.
What could be the reason for excluding a cohort that
includes so many of the individuals whose characteris-
tics are being studied—especially when those individu-
als are, very literally, a captive population?
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In reply
I thank Pieper and colleagues for sharing their insights on
the problem with CVD among injection drug users and for
reminding readers that the medical, social, and psychiatric
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